Community platinum use in neoadjuvant or adjuvant HER2-breast cancer.

被引：0
|
作者：
Bobolts, Laura Rose
Armitage, Melissa
Tamayo, Mary Michelle
Hrushesky, William J.
Kogler, Jurgen
Schorer, Anna E.
Wurtz, Kenneth
Bennett, Charles L.
Shimp, William S.
Baranwal, Anmol
Huff, Dinah Faith Q.
Anthony, Carol
Walton, Robert
Fishman, Marc L.
机构：
[1] Oncol Analyt Inc, Plantation, FL USA
[2] Nova SE Univ, Coll Pharm, Ft Lauderdale, FL 33314 USA
[3] Onc Analyt, W Orange, NJ USA
[4] South Carolina Coll Pharm, Columbia, SC USA
[5] Oncol Analyt, Lonsdale, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12029
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Hormone receptor alterations and treatment responses after neoadjuvant therapy in patients with ER+/HER2-breast cancer.
    Maeda, Shigeto
    Tohyama, Hiroaki
    Tokai, Yukiko
    Nakashima, Kazuaki
    Kamohara, Yukio
    Nagata, Yasuhiro
    Ito, Masahiro
    Fujioka, Hikaru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Use of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
    Elkerm, Y.
    Ali, I. M.
    Elsaid, A. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [5] Community use of anthracyclines for adjuvant HER2-positive breast cancer (BC).
    Kumar, Akhil
    Fishman, Marc L.
    Shimp, William S.
    Bobolts, Laura Rose
    Krook, James Edward
    Fishman, Val
    Davis, Sharon
    Huff, Dinah
    Anthony, Carol
    Walton, Robert
    Hrushesky, William J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Neoadjuvant pembrolizumab plus decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer
    Bear, Harry Douglas
    Idowu, Michael O.
    Poklepovic, Andrew
    Sima, Adam
    Kmieciak, Maciej
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [7] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    [J]. CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [8] Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2-breast cancer.
    Landsman-Blumberg, Pamela
    Namjoshi, Madhav
    Thomson, Erin
    Johnson, William
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.
    Luis, Ines Vaz
    Lin, Nancy U.
    Keating, Nancy Lynn
    Barry, William Thomas
    Lii, Joyce
    Burstein, Harold J.
    Winer, Eric P.
    Freedman, Rachel A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
12345